Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 19/20 | 1.00 |
| ▸ | FLT1 | P17948 | 1/20 | 0.55 |
| ▸ | FLT4 | P35916 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1473996 | 0.76 | IMPDH2 (1.00) | IMPDH2FLT1FLT4KDR | |
| SCHEMBL31060328 | 0.73 | KDR (0.97) | IMPDH2FLT1FLT4KDR | |
| SCHEMBL5319080 | 0.71 | IMPDH2 (0.59) | IMPDH2FLT1FLT4KDR | |
| SCHEMBL31061326 | 0.71 | KDR (1.00) | IMPDH2FLT1FLT4KDR | |
| Gw549390X SCHEMBL3295009 | 0.69 | KDR (1.00) | IMPDH2FLT1FLT4KDR | |
| SCHEMBL5502826 | 0.68 | IMPDH2 (0.68) | IMPDH2FLT1FLT4KDR | |
| Gw632046X SCHEMBL5475472 | 0.68 | KDR (1.00) | IMPDH2FLT1FLT4KDR | |
| SCHEMBL5480404 | 0.68 | KDR (0.97) | IMPDH2FLT1FLT4KDR | |
| SCHEMBL6329220 | 0.68 | KDR (0.79) | IMPDH2FLT1FLT4KDR | |
| SCHEMBL15878912 | 0.66 | KDR (0.79) | IMPDH2FLT1FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2803357-B1 | Angiogenesis inhibitors | UNIV JOHNS HOPKINS (US) | 2020-11-18 | — | — | EP | disclosed |
| US-9642865-B2 | Angiogenesis inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-05-09 | — | — | US | disclosed |
| US-8980930-B2 | Angiogenesis inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20150056267-A1 | ANGIOGENESIS INHIBITORS | UNIV JOHNS HOPKINS (US) | 2015-02-26 | — | — | US | disclosed |
| EP-2803357-A2 | Angiogenesis inhibitors | THE JOHNS-HOPKINS UNIVERSITY (US) | 2014-11-19 | — | — | EP | disclosed |
| US-20130101657-A1 | ANGIOGENESIS INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-04-25 | — | — | US | disclosed |
| US-20080193499-A1 | Angiogenesis Inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-08-14 | — | — | US | disclosed |
| EP-1765336-A2 | ANGIOGENESIS INHIBITORS | THE JOHNS-HOPKINS UNIVERSITY (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006004795-A2 | ANGIOGENESIS INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150056267-A1 | ANGIOGENESIS INHIBITORS | FLT1, VEGFA, FLT4 | IMPDH2 2862/4885FLT1 1/4885FLT4 3/4885 |
| US-20080193499-A1 | Angiogenesis Inhibitors | FLT1, VEGFA, FLT4 | IMPDH2 2862/4885FLT1 1/4885FLT4 3/4885 |
| US-20130101657-A1 | ANGIOGENESIS INHIBITORS | FLT1, VEGFA, FLT4 | IMPDH2 2862/4885FLT1 1/4885FLT4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.